BLSM ▼ -2.7% - BlossomHill Therapeutics, Inc. $BLSM - BlossomHill Therapeutics to Present Updated Data from Ongoing Phase 1/2 SOLARA Trial of its Macrocyclic OMNI-EGFR™ Inhibitor, BH-30643, in EGFR-mutant NSCLC at the 2026 World Conference on Lung Cancer BlossomHill Therapeutics fell 2.7% today following an announcement that it will present updated Phase 1/2 trial data for its EGFR inhibitor candidate at an upcoming lung cancer conference. The stock's decline suggests investors may have interpreted the timing or nature of the presentation as not warranting an immediate positive reaction, despite the company advancing its clinical program in non-small cell lung cancer. 01-SEP-2026 07:01 AM ET